Sino Biopharmaceutical is acquiring the remaining stake in LaNova Medicines for US $950.9 million to bolster its cancer drug ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Both AstraZeneca and MSD have secured lucrative licensing deals for two of LaNova’s oncology assets in recent years.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

AstraZeneca PLC (NASDAQ:AZN) is one of the best high growth stocks. Bloomberg reported on July 3 that AstraZeneca is engaged ...

STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions of dollars in ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.